540.20
-0.90
(-0.17%)
At close: January 31 at 5:24:11 PM GMT+1
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 24 | 22 | 34 | 31 |
| Avg. Estimate | 7.12B | 7.78B | 31.54B | 35.44B |
| Low Estimate | 7B | 7.64B | 31.03B | 34.81B |
| High Estimate | 7.25B | 7.95B | 31.89B | 36.8B |
| Year Ago Sales | 6.35B | 6.96B | 28.17B | 31.54B |
| Sales Growth (year/est) | 12.16% | 11.73% | 11.99% | 12.35% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| M4I.F | -- | -- | -- | -- |
| S&P 500 | 10.39% | 9.41% | 13.53% | 14.03% |
Upgrades & Downgrades
| Maintains | Macquarie: Outperform to Outperform | 1/31/2025 |
| Maintains | Citigroup: Buy to Buy | 1/31/2025 |
| Maintains | UBS: Buy to Buy | 1/31/2025 |
| Maintains | RBC Capital: Outperform to Outperform | 1/31/2025 |
| Reiterates | Piper Sandler: Overweight to Overweight | 1/31/2025 |
| Maintains | JP Morgan: Overweight to Overweight | 1/31/2025 |